{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:45:58Z","timestamp":1793234758501,"version":"4.5.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T00:00:00Z","timestamp":1623715200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T00:00:00Z","timestamp":1623715200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Dermatol"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1111\/bjd.20431","type":"journal-article","created":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T03:23:37Z","timestamp":1620098617000},"page":"745-755","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study*"],"prefix":"10.1093","volume":"185","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2971-0199","authenticated-orcid":false,"given":"D.F.","family":"Murrell","sequence":"first","affiliation":[{"name":"Department of Dermatology St George Hospital University of New South Wales Faculty of Medicine Sydney NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Patsatsi","sequence":"additional","affiliation":[{"name":"2nd Dermatology Department Aristotle University Faculty of Medicine Papageorgiou General Hospital Thessaloniki Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Stavropoulos","sequence":"additional","affiliation":[{"name":"1st Department of Dermatology National and Kapodistrian University School of Medicine Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Baum","sequence":"additional","affiliation":[{"name":"Department of Dermatology Sheba Medical Center, Ramat Gan, Israel and Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Zeeli","sequence":"additional","affiliation":[{"name":"Department of Dermatology Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.S.","family":"Kern","sequence":"additional","affiliation":[{"name":"Dermatology Department The Royal Melbourne Hospital Faculty of Medicine, Dentistry and Health Sciences the University of Melbourne Melbourne VIC Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.\u2010V.","family":"Roussaki\u2010Schulze","sequence":"additional","affiliation":[{"name":"Department of Dermatology University General Hospital of Larissa Larissa Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Sinclair","sequence":"additional","affiliation":[{"name":"University of Melbourne and Sinclair Dermatology Melbourne VIC Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.D.","family":"Bassukas","sequence":"additional","affiliation":[{"name":"Department of Skin and Venereal Diseases School of Health Sciences University of Ioannina Ioannina Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Thomas","sequence":"additional","affiliation":[{"name":"Principia Biopharma Inc., a Sanofi Company South San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Neale","sequence":"additional","affiliation":[{"name":"Principia Biopharma Inc., a Sanofi Company South San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Arora","sequence":"additional","affiliation":[{"name":"Principia Biopharma Inc., a Sanofi Company South San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Caux","sequence":"additional","affiliation":[{"name":"Department of Dermatology Groupe Hospitalier Paris Seine\u2010Saint\u2010Denis AP\u2010HP Bobigny France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3030-5369","authenticated-orcid":false,"given":"V.P.","family":"Werth","sequence":"additional","affiliation":[{"name":"University of Pennsylvania and Corporal Michael J. Crescenz VAMC Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.G.","family":"Gourlay","sequence":"additional","affiliation":[{"name":"Principia Biopharma Inc., a Sanofi Company South San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Joly","sequence":"additional","affiliation":[{"name":"Department of Dermatology Rouen University Hospital Centre de R\u00e9f\u00e9rence des Maladies Bulleuses Autoimmunes, and INSERM U1234 Normandie University Rouen France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the BELIEVE trial investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,6,15]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01418"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.5954"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.02.021"},{"key":"e_1_2_7_5_1","volume-title":"Dermatopathology","author":"Kempf W","year":"2008"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30070-3"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31778-7"},{"key":"e_1_2_7_8_1","volume-title":"Rituxan (rituximab) [prescribing information]","year":"2019"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.1817"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0779-z"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13351"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2020.03.579"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2001130"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-eular.3641"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12878"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12649"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.144.1.25"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.01.012"},{"key":"e_1_2_7_19_1","unstructured":"CTCAE.Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. US Department of Health and Human Services; National Institutes of Health National Cancer Institute v4.03: 14 June 2010."},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12772"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.72"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.4972"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/82.5.1074"},{"key":"e_1_2_7_24_1","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.4049\/jimmunol.159.4.2010","article-title":"Characterization of autoantibodies in pemphigus using antigen\u2010specific enzyme\u2010linked immunosorbent assays with baculovirus\u2010expressed recombinant desmogleins","volume":"159","author":"Ishii K","year":"1997","journal-title":"J Immunol"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevImmunol.2018025184"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19173"},{"key":"e_1_2_7_27_1","volume-title":"Calquence (acalabrutinib) [prescribing information]","year":"2019"},{"key":"e_1_2_7_28_1","volume-title":"Imbruvica (ibrutinib) [prescribing information]","year":"2020"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12841"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.04.042"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjd.20431","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjd.20431","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjd.20431","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T06:35:01Z","timestamp":1698993301000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/185\/4\/745\/6599959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,15]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1111\/bjd.20431"],"URL":"https:\/\/doi.org\/10.1111\/bjd.20431","archive":["Portico"],"relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,15]]},"assertion":[{"value":"2021-04-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}